OJSC Gedeon Richter is one of the largest Eastern European pharmaceutical manufacturers. The company has mastered the production of 200 types of drugs, a fifth of which are its own unique developments.
Way to success
The first Gedeon Richter pharmacy opened in 1901 in Budapest, Hungary. At that time, pharmacists prepared their own medicines. A laboratory was equipped at the pharmacy, where the production of organotherapeutic drugs made from extracts of cattle glands was organized.
6 years later, the first plant began operating, and the production of lecithins, vitamins and other components was launched. Later they mastered the processing of plant raw materials: salicylic acid derivatives appeared. By the way, the drug “Calmopirin”, mastered in 1912, is still used today. By 1914, Gedeon Richter had patented 24 drugs, becoming a strategic pharmaceutical enterprise in Austria-Hungary.
The pill that changed the world
With the beginning of the “era of contraception” in the 60s, many associate such a phenomenon as a significant change in the social status of women in society. Contraceptive drugs have made it possible to prevent unplanned pregnancy 100%.
It was the outstanding pharmacist from Budapest Gedeon Richter who stood at the origins of hormonal synthesis and worked on the first contraceptive pill. The production of gynecological drugs began from the very foundation of the company in 1901, together with the development of the first organotherapeutic drugs. In 1939, the company developed a technology for isolating estrone and established industrial production of crystalline estrone. The success was consolidated by the creation of synthetic testosterone and progesterone.
"Gedeon Richter": drugs
In the 1950s, a key hormone synthesis compound was created, used to produce sex hormones (progesterone, estrone and testosterone), non-steroidal anabolic agents and oral contraceptives.
Since the early 1960s, the Gedeon Richter company began to use the most modern production technologies, including sterile fermentation. Subsequently, thanks to new technologies, it became possible to manufacture new active substances, such as norgestrel, levonorgestrel and their derivatives, resulting in the creation of a combined hormonal contraceptive, released in 1966. The company also brought hormonal contraception to the USSR for the first time.
Now fourth-generation drugs have appeared, which, for example, contain drospirenone as an active component. Being a synthetic hormone, it is similar to progesterone produced by the body.
Quality
Production control and compliance with all best standards are of utmost importance in the production of hormonal drugs. Simply put, it is important to understand exactly how and under what technological conditions hormonal drugs are synthesized in order to confidently speak about the quality of the product and minimize undesirable effects. In the world, a few large concerns have their own synthesis of sex steroids. Pharmaceutical production is equipped with high-performance liquid chromatography, nuclear magnetic resonance and other high-tech assistants.
Substances for the manufacture of drugs and the hormonal components themselves are produced in Hungary, which allows you to trace all stages of production and be confident in the result. It is this quality and approach that doctors and patients, as well as scientists in those countries where the company supplies its famous substances, trust.
Development
Today, the key factor in determining the weight of a company is intellectual capital, so leading companies need to invest in R&D (research and development). For the pharmaceutical business, this means that the core of development becomes research activities in the development of new products and practical solutions. It is noteworthy that Gedeon Richter is the only Eastern European company included in the TOP 200 in the category of innovation costs with an indicator of 12% of annual turnover.
In 2010, the joint-stock company bought out the Swiss biopharmaceutical company Preglem. It offers molecules for the treatment of complex gynecological diseases such as uterine fibroids, endometriosis and others.
"Gedeon Richter-Rus"
The company produces about two hundred types of drugs in more than 400 release forms. As part of the future strategy, it was decided in 1996 to create a separate production facility in Central Russia. Hungarian pharmacists built one of five subsidiaries in the Yegoryevsky district near Moscow. It produces:
- finished medications;
- intermediate connections;
- active substances.
Thus, Gedeon Richter-Rus became the first foreign pharmaceutical enterprise in Russia. Today, the plant not only supplies the domestic market, but also exports medicines to the CIS countries (Georgia, Armenia, Moldova, Azerbaijan).
For the benefit of society
The current situation involves the joint work of scientists - pharmacists and doctors for the benefit of society. Gedeon Richter initiates and supports events at various levels in Russia:
- scientific and practical conferences;
- seminars, congresses;
- international forums.
The task of preserving women's reproductive health must be addressed at all levels. Following this logic, Gedeon Richter regularly carries out educational and other support activities for the professional community. For example, Hungarian pharmacists have been sponsoring the “Russia’s Reproductive Tomorrow” award for many years. The award winners make an invaluable contribution to the development of the Russian school of obstetrics and gynecology.
Gedeon Richter has a scientific base at the level of the highest world standards; its own scientific developments have allowed the company to significantly expand the range of gynecological drugs. A wide selection helps specialists and women make important decisions in their lives, while the quality and range of hormonal contraceptives continues to improve.
assortment of medicinal market
The company receives most of its income from the sale of generic drugs, but this category includes a special group of products - steroids, which provides the company with large profits. Over the past decade, gynecological drugs have contributed significantly to good results, both in terms of revenue growth and achieving a higher profit share.
The company produces about one hundred types of pharmaceuticals in more than 170 forms. Gedeon Richter constantly updates its range, develops dosage forms and creates fundamentally new drugs.
Fig.1.
Richter sells original drugs and conducts extensive research into compounds that act on diseases of the central nervous system.
In the company's portfolio, original drugs make up 15-20%, licensed ones - 12% and 70-75% - branded generics.
Fig.2.
The company’s medicinal product range is presented in 8 main areas:
1. The gynecological area is represented by a wide range of combined oral contraceptives (COCs), emergency contraception drugs (Postinor and Escapelle), drugs for hormone replacement therapy for menopause and other drugs that are used in obstetric and gynecological practice. The CPC group is represented by both the traditional and well-known Ovidon, Rigevidon and Tri-Regol, as well as the modern promising drugs Novinet, Regulon, Lindinet-20, Lindinet-30 and Tristin. All PDAs produced by Richter Gedeon have proven themselves to be very reliable and safe drugs for the prevention of unwanted pregnancy and the treatment of gynecological pathologies. They are available to most women and have convenient packaging for both one and three cycles of use. The drug Pauzogest has been successfully used for hormone replacement therapy during menopause.
2. The cardiological direction is represented by a group of drugs for the treatment of arterial hypertension, heart failure and coronary heart disease. Diroton is a drug for the treatment of arterial hypertension and heart failure. This drug has a number of valuable properties that make it possible to prescribe it to patients with arterial hypertension, heart failure in combination with diabetes mellitus, excess body weight, and liver dysfunction. A serious problem today is coronary heart disease, for the solution of which Richter Gedeon offers the drug Normodipin. For the treatment of arterial hypertension, Richter Gedeon offers the combined drug Equator.
3. The neurological direction is represented primarily by the world-famous brands Cavinton and Mydocalm - original developments of Richter Gedeon. Thousands of neurologists, neurosurgeons, therapists, ophthalmologists, and doctors of other specialties have been convinced from their own clinical experience: Cavinton is a reliable friend, the one who really helps in a difficult moment for their patient. As for Mydocalm, it has recently been experiencing a worldwide renaissance: in Germany, Japan, and many other countries, multicenter studies were conducted in compliance with the requirements of evidence-based medicine, which confirmed the high efficiency and safety of Mydocalm in the treatment of patients with pathologies of the musculoskeletal system, especially with back pain syndrome. New products on the pharmaceutical market are the drugs Rexetine (treatment of anxiety), Tebantin (treatment of neuropathic pain) and Andante (hypnotic with a mild therapeutic profile).
4. The dermato-mycological direction is represented by both well-known drugs for external use (Mikozolon, Dermazolon, Fluorocort, Aurobin ointments), and fairly new antifungal agents - Mikosist, Terbizil, and also Ginofort. Mikosist, which has 5 convenient release forms, has established itself as an effective drug for the treatment of various types of candidiasis.
5. When treating patients with gastric and duodenal ulcers, gastroesophageal reflux disease, gastritis, functional dyspepsia and other pathologies of the gastrointestinal tract, the gastroenterological drug Kvamatel (famotidine) is successfully used, and the injection form of this drug is an integral component of the effective preparation of the patient for operating rooms interventions to reduce the acid-producing function of the stomach and prevent bleeding. Kvamatel and Gordox are included in the standards for the treatment of acute and exacerbations of chronic pancreatitis.
6. The urological area is relatively new in the Richter Gedeon portfolio. It is represented by the drugs Tamsol and Prosteride, which are successfully used to treat benign prostatic hyperplasia, as well as the non-steroidal antiandrogen drug Calumide for the treatment of hormone-dependent prostate cancer.
7. The hospital area probably does not require a separate presentation, since medical personnel of large and small clinics, hospitals, multidisciplinary and specialized hospitals, and research institutes have been working with these drugs for several decades. The main quality criterion for Arduan, Vinblastina-Richter, Vincristina-Richter, Haloperidol, Haloperidol Decanoate, Hydrocortisone-Richter, Gordox, Calypsol, Klion d/infusions, Mikosist d/infusions, Oxytocin is the positive experience of using these drugs for a wide variety of pathologies. Predictable effect, high-quality composition and accessibility are the main features that enable doctors to believe in them and prescribe them to their patients again and again.
8. The direction of over-the-counter drugs (OTC) was separated into a separate direction in 2007. These drugs can be used without a doctor’s prescription, and the pharmacist is the main figure on whom the correct use of them by the patient depends. This group includes the drugs Panangin, Terbizil cream 1%, Kvamatel mini dragees, Curiosin gel, Ftorokort ointment and Mikosist in capsules.
These OTC drugs are strategic in the company’s portfolio and active activities are carried out on them (broadcast television advertising, publications in specialized and general publications, visits of medical representatives to pharmacies, etc.).
Fig.3.
More than 30% of the plant’s drugs are sold in the CIS countries. Over the past years, Gedeon Richter has been a leader in the supply of medicines to Russia. The range includes about 90 drugs of various therapeutic groups.
In 2008, Gedeon Richter's share in the Russian market was 2.3%; Russia accounts for 70% of the company's total turnover in the CIS.
Among the drugs in greatest demand on the Russian market are: Prednisolone, Postinor, Oxytocin, Mydocalm, Bromocriptine, Regulon, Novinet, Lindinet, Diroton, Normodipine, Mikosist, Terbizil and Equator.
About 40% of drugs registered in Russia are included in the Federal List of Vital and Essential Medicines. These include Normodipin, Mammozol, Bidop, Vinpocetine, Panangin, Metformin, Postinor, Veroshpiron, Retabolil and many others.
Tab. 1. Assortment of medicines from Gedeon Richter.
|
Tradename |
INN / composition |
Pharmacotherapeutic group |
Actual number of offers |
|
obstetrics and gynecology |
|||
|
Anteovin Table/set No. 63 |
|||
|
Gynofort Cream vag. 2% applicators 5g |
Butoconazole |
antifungal agent |
|
|
Klion R-r d/inf. 0.5% (500 mg/100 ml): vial. 100 ml. |
Metronidazole |
||
|
Klion-D 100 (Klion-D 100) Tab. vag. 100mg+100mg No. 10 |
Metronidazole + miconazole (Metronidazole + miconazole) |
combined antimicrobial agent (antimicrobial + antifungal) |
|
|
Lactinette Tab. p.p.o. 75 mcg No. 28 |
Desogestrel |
gestagen |
|
|
Lindynette 20 Tab. By. 75 mcg+20 mcg No. 21 |
combined contraceptive (estrogen + gestagen) |
||
|
Lindynette 20 Tab. By. 75 mcg+20 mcg No. 63 |
Gestodene + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Lindynette 30 Tab. By. 75 mcg+30 mcg No. 21 |
Gestodene + Ethinylestradiol (Gestodene + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Lindynette 30 Tab. By. 75 mcg+30 mcg No. 63 |
Gestodene + Ethinylestradiol (Gestodene + Ethinylestradiol) |
combined contraceptive (estrogen + gestagen) |
|
|
Mycosyst R-r d/inf. 2 mg/ml bottle. 100 ml. No. 1 |
Fluconazole |
||
|
Mycosyst Caps. 150 mg №1 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 150 mg No. 2 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 150 mg No. 7 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 150 mg No. 28 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg No. 1 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg No. 2 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg No. 7 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 100 mg No. 28 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg No. 1 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg No. 2 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg No. 7 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Mycosyst Caps. 50 mg No. 28 |
Fluconazole |
broad spectrum antifungal agent |
|
|
Microfollin Tab. 50 mcg No. 10 |
Ethinyl estradiol |
estrogen |
|
|
Novynette Tab. p.p.o. 150mcg+20mcg No. 21 |
combined contraceptive (estrogen + gestagen) |
||
|
Novynette Tab. p.p.o. 150mcg+20mcg No. 63 |
Desogestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Norkolut Tab. 5 mg No. 20 |
Norethisterone |
gestagen |
|
|
Ovidon |
(Levonorgestrel + Ethinylestradiol) |
contraceptive, estrogen |
|
|
Oxytocin Solution for intravenous and intramuscular injection. 5 IU/1 ml. amp. No. 5 |
Oxytocin |
labor stimulant - oxytocin drug |
|
|
Ostalon Tab. By. 70mg №4 |
Alendronic acid |
bone resorption inhibitor - bisphosphonate |
|
|
Tab. p.p.o./set No. 32 |
|||
|
Ostalon Calcium -D Tab. p.p.o./set No. 96 |
Colecalciferol + calcium carbonate + alendronic acid (Colecaiciferol+ calcium carbonate + alendronic acid) |
osteoporosis combined treatment (bone resorption inhibitor+calcium-phosphorus metabolism regulator+calcium drug) |
|
|
Pausogest Tab. p.p.o. No. 28 |
|||
|
Pausogest Tab. p.p.o. №28*3 |
Norethisterone + Estradiol |
combined antimenopausal agent (estrogen + gestagen) |
|
|
Postinor Tab. 0.75 mg №2 |
gestagen |
||
|
Regulon Tab. p.p.o. 150mcg+30mcg No. 21 |
Desogestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Regulon Tab. p.p.o. 150mcg+30mcg No. 63 |
Desogestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon Tab. By. 150 mcg+30 mcg No. 21 |
Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon Tab. By. 150 mcg+30 mcg No. 63 |
Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon 21+7 Tab. By. 30 mcg+150 mcg No. 28 |
Levonorgestrel + Ethinyl estradiol Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Rigevidon 21+7 (Rigevidon 21+7) Tab. By. 30 mcg+150 mcg No. 28*3 |
Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Triaklim Table p.p.o. No. 28 and 28*3 |
Norethisterone + Estradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Tri-regol Tab. By. No. 21 |
Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen. |
|
|
Tri-regol Tab. By. No. 63 |
Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Tab.p.o. No. 28 |
Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Tri-regol 21+7 (Tri-regol 21+7) Tab.p.o. №28*3 |
Levonorgestrel + Ethinylestradiol |
combined contraceptive (estrogen + gestagen) |
|
|
Escapelle Tab. 1.5 mg №1 |
Levonorgestrel |
gestagen |
|
|
Estrimaks (Estrimax) Tab. p.p.o. 2 mg No. 28 |
Estradiol |
||
|
Estrimaks (Estrimax) Tab. p.p.o. 2 mg No. 28*3 |
Estradiol |
Antimenopausal estrogen drug |
|
|
Anesthesiology |
|||
|
Calypsol Solution for injection. 500 mg/10 ml: vial. No. 5 |
Ketamine |
anesthetic |
|
|
Sombrevin R-r d/in. 5 %; amp. 10 ml No. 5 |
Propanidid |
anesthetic |
|
|
Fentanyl R-r d/in. 0.05 mg/ml. amp. 10 ml No. 50 |
Fentanyl |
analgesic (opioid) drug |
|
|
Gastroenterology |
|||
|
Vermox Tab. 100 mg No. 6 |
Mebendazole |
anthelmintic |
|
|
Histodil R-r d/in. 200 mg/2 ml; amp. 2 ml No. 10 |
Cimetidine |
antiulcer agent |
|
|
Histodil Tab. 0.2 g No. 50 |
Cimetidine |
antiulcer agent |
|
|
Decaris Tab. 50 mg No. 1 |
Levamisole |
anthelmintic |
|
|
Decaris Tab. 50 mg No. 2 |
Levamisole |
anthelmintic |
|
|
Decaris Tab. 150 mg №1 |
Levamisole |
anthelmintic |
|
|
Decaris Tab. 150 mg No. 2 |
Levamisole |
anthelmintic |
|
|
Quamatel Tab. p.p.o. 20 mg No. 14 |
Famotidine |
||
|
Quamatel Tab. p.p.o. 20 mg No. 28 |
Famotidine |
a drug that reduces the secretion of gastric glands - H2-histamine receptor blocker |
|
|
Quamatel Tab. p.p.o. 40 mg No. 14 |
Famotidine |
a drug that reduces the secretion of gastric glands - H2-histamine receptor blocker |
|
|
Quamatel Liof-t for preparation. solution for injection 20 mg vial No. 5 included with solution |
Famotidine |
a drug that reduces the secretion of gastric glands - H2-histamine receptor blocker |
|
|
Quamatel Tab. p.p.o. 40 mg No. 14 |
Famotidine |
a drug that reduces the secretion of gastric glands - H2-histamine receptor blocker |
|
|
Quamatel mini Tab. p.p.o. 10 mg No. 14 |
Famotidine |
a drug that reduces the secretion of gastric glands - H2-histamine receptor blocker |
|
|
Klion Tab. 250 mg No. 20 |
Metronidazole |
antimicrobial and antiprotozoal agent |
|
|
Nifuroxazide - Richter Nifuroxazide-Richter Susp. for oral administration 220 mg/5 ml vial. 90 ml included with dosage spoon |
Nifuroxazide |
||
|
Nifuroxazide - Richter Nifuroxazide-Richter Tab. p.p.o.100 mg No. 24 |
Nifuroxazide |
Intestinal antiseptic. Antidiarrheal drug |
|
|
Omeprazol-Richter Caps. 20 mg No. 14 |
Omeprazole |
antiulcer |
|
|
Sirepar R-r d/in.; fl. 10 ml No. 5 |
hepatoprotector |
||
|
Dermatology |
|||
|
Dermosolon Ointment for external application approx. 5mg+30 mg/1g 5g |
Clioquinol + Prednisolone |
glucocorticosteroid in combination |
|
|
Curiosin Gel 1% 15 g. |
tissue repair stimulator |
||
|
Mycosolon Ointment for external use approx. 15 g |
Mazipredone + Miconazole (Mazipredone + Miconazole) |
antifungal agent |
|
|
Terbisil Cream for external use approx. 1% 15g |
Terbinafine |
antifungal agent |
|
|
Terbisil Tab. 125 mg No. 14 |
Terbinafine |
antifungal agent |
|
|
Terbisil Tab. 125 mg No. 28 |
Terbinafine |
antifungal agent |
|
|
Terbisil Tab. 250 mg No. 14 |
Terbinafine |
antifungal agent |
|
|
Terbisil Tab. 250 mg No. 28 |
Terbinafine |
antifungal agent |
|
|
Fluorocort Ointment for external use approx. 0.1% 15g |
Triamcinolone |
External glucocorticosteroid appl. |
|
|
Immunology |
|||
|
Avonex Liof. d/r-ra d/v/m input. 30 mcg |
Interferon beta-1a |
Interferon preparation |
|
|
Groprinosin Tab. 500 mg No. 50 |
Inosine pranobex |
Immunostimulating drug |
|
|
Clargotil Syrup 5 mg/5 ml 120 ml |
Loratadine |
||
|
Clargotil Tab. 10 mg No. 10 |
Loratadine |
antiallergic agent - H1-histamine receptor blocker |
|
|
Lordestin Tab. p.p.o. 5 mg. No. 10 |
Desloratadine |
antiallergic agent - H1-histamine receptor blocker |
|
|
Lordestin Tab. p.p.o. 5 mg. No. 30 |
Desloratadine |
antiallergic agent - H1-histamine receptor blocker |
|
|
Filergim Solution for intravenous and subcutaneous administration of 30 million IU, 1 ml syringes. No. 1 |
Filgrastim |
leukopoiesis stimulator |
|
|
Filergim Solution for intravenous and subcutaneous administration 48 million IU, 0.5 ml syringes. No. 1 |
Filgrastim |
leukopoiesis stimulator |
|
|
Cardiology |
|||
|
Bidop Tab. 5 mg No. 14 |
Bisoprolol |
||
|
Bidop Tab. 5 mg No. 28 |
Bisoprolol |
selective beta1-blocker |
|
|
Bidop Tab. 5 mg No. 56 |
Bisoprolol |
selective beta1-blocker |
|
|
Bidop Tab. 10 mg No. 14 |
Bisoprolol |
selective beta1-blocker |
|
|
Bidop Tab. 10 mg No. 28 |
Bisoprolol |
selective beta1-blocker |
|
|
Bidop Tab. 10 mg No. 56 |
Bisoprolol |
selective beta1-blocker |
|
|
Verospiron Tab.25mg. No. 20 |
|||
|
Verospiron Caps. 50mg No. 30 |
Spironolactone |
diuretic potassium-sparing agent |
|
|
Verospiron 9Verospiron) Caps.100mg. No. 30 |
Spironolactone |
diuretic potassium-sparing agent |
|
|
Heparin-Richter R-r d/in. 25000 IU/5 ml; fl. 5 ml |
Heparin sodium |
anticoagulant |
|
|
Digoxin Tab. 0.25 mg No. 50 |
Digoxin |
cardiotonic agent - cardiac glycoside |
|
|
Diroton Tab. 2.5 mg No. 14 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 2.5 mg No. 28 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 2.5 mg No. 56 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 5 mg No. 14 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 5 mg No. 28 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 5 mg No. 56 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 10 mg No. 14 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 10 mg No. 28 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 10 mg No. 56 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 20 mg No. 14 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 20 mg No. 28 |
Lisinopril |
ACE inhibitor |
|
|
Diroton Tab. 20 mg No. 56 |
Lisinopril |
ACE inhibitor |
|
|
Tab. p.p.o. 50 mg No. 10 |
Losartan (Losartanum) |
||
|
Losartan Richter Tab. p.p.o. 50 mg No. 30 |
Losartan (Losartanum) |
angiotensin II receptor antagonist- |
|
|
Losartan Richter Tab. p.p.o. 100 mg No. 10 |
Losartan (Losartanum) |
angiotensin II receptor antagonist |
|
|
Losartan Richter Tab. p.p.o. 100 mg No. 30 |
Losartan (Losartanum) |
angiotensin II receptor antagonist |
|
|
Losartan-N Richter Tab. p.p.o. 12.5 mg+50 mg No. 30 |
|||
|
Tab. p.p.o. 12.5 mg+100 mg No. 30 |
Losartan + hydrochlorothiazide (Losartanum + hydrochlorothiazide) |
combined antihypertensive drug (angiotensin II receptor antagonist + diuretic) |
|
|
Losartan-N Richter 9Lazartan-N Richter) Tab. p.p.o. 25 mg+100 mg No. 30 |
Losartan + hydrochlorothiazide (Losartanum + hydrochlorothiazide) |
combined antihypertensive drug (angiotensin II receptor antagonist + diuretic) |
|
|
Co-Diroton Tab. 12.5 mg + 10 mg No. 10 |
Hydrochlorothiazide + Lisinopril |
||
|
Co-Diroton Tab. 12.5 mg + 10 mg No. 30 |
Hydrochlorothiazide + Lisinopril (Lisinopril + hydrochlorothiazide) |
combined antihypertensive drug (ACE inhibitor + diuretic) |
|
|
Co-Diroton Tab. 12.5 mg + 20 mg No. 10 |
Hydrochlorothiazide + Lisinopril (Lisinopril + hydrochlorothiazide) |
combined antihypertensive drug (ACE inhibitor + diuretic) |
|
|
Co-Diroton Tab. 12.5 mg + 20 mg No. 30 |
Hydrochlorothiazide + Lisinopril (Lisinopril + hydrochlorothiazide) |
combined antihypertensive drug (ACE inhibitor + diuretic) |
|
|
Mertenil Tab. p.p.o. 5 mg No. 30 |
Rosuvastatin |
||
|
Mertenil Tab. p.p.o. 10 mg No. 30 |
Rosuvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Mertenil Tab. p.p.o. 20 mg No. 30 |
Rosuvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Mertenil Tab. p.p.o. 40 mg No. 30 |
Rosuvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Normodipine Tab. 5 mg. No. 10 |
Amlodipine |
||
|
Normodipine Tab. 5 mg. No. 30 |
Amlodipine |
blocker of "slow" calcium channels |
|
|
Normodipine Tab. 10 mg. No. 10 |
Amlodipine |
blocker of "slow" calcium channels |
|
|
Normodipine Tab. 10 mg. No. 30 |
Amlodipine |
blocker of "slow" calcium channels |
|
|
Nortivan Tab. p.p.o. 40 mg No. 30 |
Valsartan |
angiotensin II receptor antagonist |
|
|
Nortivan Tab. p.p.o. 80 mg No. 30 |
Valsartan |
angiotensin II receptor antagonist |
|
|
Nortivan Tab. p.p.o. 160 mg No. 30 |
Valsartan |
angiotensin II receptor antagonist |
|
|
Panangin Tab. p.p.o. 158 mg.+140 mg. No. 50 |
potassium and magnesium preparation |
||
|
Panangin R-r d/v/input. 452 mg+400 mg/10 ml amp. No. 5 |
Potassium aspartate and magnesium aspartate |
potassium and magnesium preparation |
|
|
Predizin Tab. By. 20 mg No. 30 |
Trimetazidine |
antihypoxic agent |
|
|
Predizin Tab. retard p.o. 35 mg No. 60 |
Trimetazidine |
antihypoxic agent |
|
|
Roglit Tab. By. 2mg.№60 |
Rosiglitazone |
||
|
Roglit Tab. By. 4mg.№30 |
Rosiglitazone |
oral hypoglycemic agent |
|
|
Roglit Tab. By. 4mg.№60 |
Rosiglitazone |
oral hypoglycemic agent |
|
|
Roglit Tab. By. 8mg.№30 |
Rosiglitazone |
oral hypoglycemic agent |
|
|
Simvastol Tab. p.p.o. 10 mg No. 14 |
Simvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 10 mg No. 28 |
Simvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 20 mg No. 14 |
Simvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 20 mg No. 28 |
Simvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 40 mg No. 14 |
Simvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Simvastol Tab. p.p.o. 40 mg No. 28 |
Simvastatin |
lipid-lowering agent - HMG-CoA reductase inhibitor |
|
|
Ednyt Tab. 2.5 mg No. 20 |
Enalapril |
ACE inhibitor |
|
|
Ednyt Tab. 2.5 mg No. 100 |
Enalapril |
ACE inhibitor |
|
|
Ednyt Tab. 5 mg No. 20 |
Enalapril |
ACE inhibitor |
|
|
Ednyt Tab. 5 mg No. 100 |
Enalapril |
ACE inhibitor |
|
|
Ednyt Tab. 10 mg No. 20 |
Enalapril |
ACE inhibitor |
|
|
Ednyt Tab. 10 mg No. 100 |
Enalapril |
ACE inhibitor |
|
|
Ednyt Tab. 20 mg No. 20 |
Enalapril |
ACE inhibitor |
|
|
Ednyt Tab. 20 mg No. 100 |
Enalapril |
ACE inhibitor |
|
|
Equator Tab. 5 mg+10 mg No. 10 |
|||
|
Equator Tab. 5 mg+10 mg No. 20 |
Amlodipine + Lisinopril (Amlodipine + Lisinopril) |
combined antihypertensive drug (ACE inhibitor + BMCC) |
|
|
Equator Tab. 5 mg+10 mg No. 30 |
Amlodipine + Lisinopril (Amlodipine + Lisinopril) |
combined antihypertensive drug (ACE inhibitor + BMCC) |
|
|
Equator Tab. 10 mg+20 mg No. 10 |
Amlodipine + Lisinopril (Amlodipine + Lisinopril) |
combined antihypertensive drug (ACE inhibitor + BMCC) |
|
|
Equator Tab. 10 mg+20 mg No. 30 |
Amlodipine + Lisinopril (Amlodipine + Lisinopril) |
combined antihypertensive drug (ACE inhibitor + BMCC) |
|
|
Equator Tab. 10 mg+20 mg No. 60 |
Amlodipine + Lisinopril (Amlodipine + Lisinopril) |
combined antihypertensive drug (ACE inhibitor + BMCC) |
|
|
Neurology and Psychiatry |
|||
|
Andante Caps. 5mg No. 7 |
Zaleplon |
sleeping pill |
|
|
Andante Caps. 5mg No. 14 |
Zaleplon |
sleeping pill |
|
|
Andante Caps. 10 mg No. 7 |
Zaleplon |
sleeping pill |
|
|
Andante Caps. 10mg No. 14 |
Zaleplon |
sleeping pill |
|
|
Vinpocetine Tab. 5 mg No. 50 |
Vinpocetine |
||
|
Haloperidol Tab. 1.5 mg No. 25 |
Haloperidol |
||
|
Haloperidol Tab. 1.5 mg No. 50 |
Haloperidol |
antipsychotic (neuroleptic) |
|
|
Haloperidol Tab. 5mg No. 25 |
Haloperidol |
antipsychotic (neuroleptic) |
|
|
Haloperidol Tab. 5mg No. 50 |
Haloperidol |
antipsychotic (neuroleptic) |
|
|
Haloperidol Solution d/iv and i/m injection 5 mg/1 ml amp. No. 5 |
Haloperidol |
antipsychotic (neuroleptic) |
|
|
Haloperidol decanoate R-r d/v/m insertion. (oil) 50 mg/1 ml: amp. No. 5 |
Haloperidol |
antipsychotic (neuroleptic) |
|
|
Droperidol Solution for injection. 25 mg/10 ml: vial. No. 50 |
Droperidol |
antipsychotic |
|
|
Cavinton Conc. d/prep. r-ra d/inf. 5 mg/ml: amp. 2 ml. No. 10 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton Conc. d/prep. r-ra d/inf. 5 mg/ml: amp. 10 ml No. 5 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton Tab. 5 mg No. 50 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Tab 10 mg No. 30 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Cavinton forte Tab 10 mg No. 90 |
Vinpocetine |
drug that improves cerebral blood flow |
|
|
Lamolep Tab. 25mg.№10 |
Lamotrigine |
||
|
Lamolep Tab. 50mg.№10 |
Lamotrigine |
antiepileptic drug |
|
|
Lamolep Tab. 100 mg. №10 |
Lamotrigine |
antiepileptic drug |
|
|
Lamolep Tab. 25mg.№30 |
Lamotrigine |
antiepileptic drug |
|
|
Lamolep Tab. 50mg.№30 |
Lamotrigine |
antiepileptic drug |
|
|
Lamolep Tab. 100 mg. №30 |
Lamotrigine |
antiepileptic drug |
|
|
Mydocalm-Richter Solution for intravenous and intravenous administration 100 mg+2.5 mg/ml No. 5 |
Lidocaine + Tolperisone |
||
|
Mydocalm Tab. pp o 50 mg No. 30 |
Tolperisone |
centrally acting muscle relaxant |
|
|
Mydocalm Tab. pp o 150 mg No. 30 |
Tolperisone |
centrally acting muscle relaxant |
|
|
Nantarid Tab. p.p.o. 25 mg No. 30 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 25 mg No. 60 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 100 mg No. 30 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 100 mg No. 60 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 200 mg No. 30 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 200 mg No. 60 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 300 mg No. 30 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Nantarid Tab. p.p.o. 300 mg No. 60 |
Quetiapine |
antipsychotic (neuroleptic) |
|
|
Tab. p.p.o. 400 mg No. 20 |
Piracetam |
nootropic agent |
|
|
Piracetam-Richter Tab. p.p.o. 800 mg No. 20 |
Piracetam |
nootropic agent |
|
|
Rexetin Tab. p.p.o. 20 mg No. 10 |
Paroxetine |
antidepressant |
|
|
Rexetin Tab. p.p.o. 20 mg No. 30 |
Paroxetine |
antidepressant |
|
|
Rexetin Tab. p.p.o. 30 mg No. 10 |
Paroxetine |
antidepressant |
|
|
Rexetin Tab. p.p.o. 30 mg No. 30 |
Paroxetine |
antidepressant |
|
|
Ridonex Tab. p.p.o. 1 mg No. 20 |
Risperidone |
antipsychotic (neuroleptic) |
|
|
Ridonex Tab. p.p.o. 2 mg No. 20 |
Risperidone |
antipsychotic (neuroleptic) |
|
|
Ridonex Tab. p.p.o. 4 mg No. 20 |
Risperidone |
antipsychotic (neuroleptic) |
|
|
Seduxen Tab. 5 mg No. 20 |
Diazepam |
||
|
Seduxen (Seduxen0 Solution d/iv and i/m injection 5 mg/ml amp. 2 ml. No. 5 |
Diazepam |
anxiolytic (tranquilizer) |
|
|
Stugeron Tab. 25 mg No. 50 |
Cinnarizine |
drug that improves cerebral blood flow |
|
|
Tebantin Caps. 100 mg No. 10 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin Caps. 100 mg No. 50 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin Caps. 100 mg No. 100 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin Caps. 300 mg No. 10 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin Caps. 300 mg No. 50 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin Caps. 300 mg No. 100 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin Caps. 400 mg No. 10 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin caps. 400 mg No. 50 |
Gabapentin |
antiepileptic drug |
|
|
Tebantin Caps. 400 mg No. 100 |
Gabapentin |
antiepileptic drug |
|
|
Framex Caps. 20 mg No. 14 and 28 |
Fluoxetine |
antidepressant |
|
|
Eunoctin Table 10 mg No. 10 |
Nitrazepam |
sleeping pill |
|
|
Oncology |
|||
|
Vinblastin-Richter Liof. d/prep. solution for injection 5 mg fl. No. 10 included with solution |
Vinblastine |
||
|
Vincristine-Richter Vincristine-Richter Liof. d/r-ra for intravenous injection. 1 mg with solution vial. No. 10 |
Vincristine |
antitumor agent - alkaloid |
|
|
Mammosole Tab. p.p.o. 1 mg No. 28 |
Anastrozole |
antitumor agent - estrogen synthesis inhibitor |
|
|
Calumid Tab.p.p.o. 50 mg. No. 30 |
Bicalutamide |
||
|
Calumid Tab.p.p.o. 50 mg. No. 90 |
Bicalutamide |
antitumor agent - antiandrogen |
|
|
Calumid Tab.p.p.o. 150 mg. No. 30 |
Bicalutamide |
antitumor agent - antiandrogen |
|
|
Emetron Solution for injection. 4 mg/2 ml amp. No. 5 |
Ondansetron |
||
|
Emetron Solution for injection. 8 mg/4 ml amp. No. 5 |
Ondansetron |
antiemetic - serotonin receptor antagonist |
|
|
Emetron Tab. By. 4 mg No. 10 |
Ondansetron |
antiemetic - serotonin receptor antagonist |
|
|
Emetron Tab. By. 8 mg No. 10 |
Ondansetron |
antiemetic - serotonin receptor antagonist |
|
|
Pediatrics |
|||
|
Suprax Gran. d/prep. susp. for oral administration 100 mg/5 ml: vial. 60 ml |
Cefixime |
III generation cephalosporin |
|
|
Suprax Caps. 200 mg No. 6 |
Cefixime |
III generation cephalosporin |
|
|
Suprax Caps. 400 mg No. 6 |
Cefixime |
III generation cephalosporin |
|
|
Proctology |
|||
|
Aurobin Ointment for rectal and external use. appl. 20 |
prednisolone capronate + lidocaine hydrochloride + D-panthenol (Dexpanthenol + Lidocaine + Prednisolone) |
combined glucocorticosteroid agent for local use |
|
|
Rheumatology |
|||
|
Airtal Tab. By. 100 mg No. 20 |
Aceclofenac |
||
|
Airtal Tab. By. 100 mg No. 30 |
Aceclofenac |
||
|
Airtal Tab. By. 100 mg No. 40 |
Aceclofenac |
||
|
Airtal Tab. By. 100 mg No. 60 |
Aceclofenac |
||
|
Butadion Ointment for external use approx. 5% 20g |
Phenylbutazone |
||
|
Depersolone Solution for injection. 30 mg/1 ml: amp. No. 3 |
Mazipredone |
glucocorticosteroid |
|
|
Mirlox Tab.p.o. 15mg.№20 |
Meloxicam |
||
|
Mirlox Tab.p.o. 2.5 mg. №20 |
Meloxicam |
||
|
Prednisolone Tab.5mg No. 100 fl. p/drank. |
Prednisolone |
glucocorticosteroid |
|
|
Urology |
|||
|
Prosterid Tab. p.p.o. 5mg.№14 |
Finasteride |
5-alpha reductase inhibitor |
|
|
Prosterid Tab. p.p.o. 5mg.№28 |
Finasteride |
5-alpha reductase inhibitor |
|
|
Sonizin Caps. with mod. release 0.4 mg. No. 10 |
Tamsulosin (Tamsulosinum) |
alpha1-blocker |
|
|
Sonizin Caps. with mod. release 0.4 mg. No. 30 |
Tamsulosin (Tamsulosinum) |
alpha1-blocker |
|
|
Tamsol Caps. with mod. release 0.4 mg No. 30 |
Tamsulosin (Tamsulosinum) |
alpha1-blocker |
|
|
Surgery |
|||
|
Arduan Liof. d/prep. solution for intravenous administration 4 mg vial. No. 25 included with solvent |
|||
|
Arduan Liof. d/prep. solution for intravenous administration 4 mg vial. No. 5 included with solvent |
Pipecuronium bromide |
a muscle relaxant with non-depolarizing peripheral action. |
|
|
Gordox Conc. d/prep. solution for injection 100 thousand KIE/10 ml amp. No. 25 pcs. |
Aprotinin |
fibrinolysis inhibitor - a polyvalent inhibitor of plasma proteinases. |
|
|
Klion R-r d/inf. 0.5% (500 mg/100 ml): vial. No. 1 |
Metronidazole (Metronid)azole |
antimicrobial and antiprotozoal agent |
|
|
Curiosin External size approx. 2.05 mg/1 ml vial. 10 ml with dropper |
Zinc hyaluronate |
tissue repair stimulator |
|
|
Endocrinology |
|||
|
Bromocriptin-Richter Tab. 2.5 mg No. 30 |
Bromocriptine B(romocriptine) |
dopamine receptor agonist |
|
|
Hydrocortisone-Richter Susp. d/v/sust. and peri-ost. input 25 mg+5 mg/ml vial. 5 ml. No. 1 |
Hydrocortisone + Lidocaine |
glucocorticosteroid |
|
|
Tab. p.p.o. 500 mg No. 20 |
Metformin |
||
|
Metformin-Richter Tab. p.p.o. 500 mg No. 30 |
Metformin |
hypoglycemic agent for oral administration of the biguanide group |
|
|
Metformin-Richter Tab. p.p.o. 500 mg No. 40 |
Metformin |
hypoglycemic agent for oral administration of the biguanide group |
|
|
Metformin-Richter Tab. p.p.o. 500 mg No. 60 |
Metformin |
hypoglycemic agent for oral administration of the biguanide group |
|
|
Metformin-Richter Tab. p.p.o. 850 mg No. 20 |
Metformin |
hypoglycemic agent for oral administration of the biguanide group |
|
|
Metformin-Richter Tab. p.p.o. 850 mg No. 30 |
Metformin |
hypoglycemic agent for oral administration of the biguanide group |
|
|
Metformin-Richter Tab. p.p.o. 850 mg No. 40 |
Metformin |
hypoglycemic agent for oral administration of the biguanide group |
|
|
Metformin-Richter Tab. p.p.o. 850 mg No. 60 |
Metformin |
hypoglycemic agent for oral administration of the biguanide group |
|
|
Donalgin Caps. 250 mg No. 30 |
Niflumic acid |
||
|
Retabolil Solution d/v/m. input [oily] 50 mg/ml amp. 1 ml No. 1 |
Nandrolone |
anabolic steroid drug |
There are 30 national, interregional and regional distributors engaged in the supply of medicinal products on the pharmaceutical wholesale market of the Voronezh region.
The product range, or rather its completeness, is of great socio-economic importance, since its quality determines the completeness of satisfaction of consumer demand. A narrow assortment can be one of the factors hindering the process of meeting the individual needs of each consumer. Determining the optimal assortment is a key point in the economic activity of each pharmacy organization and allows for maximum economic efficiency of its activities. For the marketing characteristics of the assortment, the assortment completeness coefficient was calculated, which is calculated as the ratio of the number of assortment items produced by the company and available on the market (actual completeness) to the number of assortment items registered in Russia and offered by suppliers.
KP=Pfact/Pbas
where KP is the coefficient of assortment completeness;
Pfact - actual completeness;
Pbaz - basic completeness.
The basic completeness is 260 drugs, taking into account different packaging and dosage. 166 positions were found among supplier companies, respectively, CP = 0.64 or 64% of drugs, which allows us to conclude that the studied company Gedeon Richter has an insufficient presence on the regional drug market.
In the pharmacy, the assortment of this company is represented by 67 items, as a result of which the CP is 0.4 or 40% of the drugs relative to the offerings of supplier companies, which indicates a low presence of medicines from the studied company Gedeon Richter in the retail market.
To determine changes in the range of medicines of the Richter company, the entry of new medicines into the Russian pharmaceutical market was studied. For this purpose, the renewal coefficient was calculated:
KO=Ofakt/Obaz
where, KO is the renewal coefficient;
Actual - the number of drugs that appeared on the regional market during the period under study;
Base - the basic quantity of drugs available on the regional market.
Of the 12 trade names of the Gedeon Richter company registered in Russia over the past five years, 10 names entered the market, i.e. Ko = 10/12 or 0.83.
The renewal coefficient for this company's medicines was 0.83, which is a fairly high indicator, indicating the active introduction of new medicines into the pharmaceutical market.
The largest number of assortment items of medicines are presented for the treatment of diseases of the cardiovascular and central nervous systems, as well as for drugs that serve to preserve the reproductive health of women.
1901 - Gedeon Richter acquired the Shas (Eagle) pharmacy in Budapest, which remains owned by the company to this day. He founded a biological laboratory for chemical experiments and began producing and marketing tonics and various organotherapeutic hormones.
1902 - Gedeon Richter's first product - Tonogen Suprarenal.
1906 - The company is founded on an area of 1000 sq. m. on Circassian Street and is the basis for the modern pharmaceutical industry in Hungary. A factory was built on the same site.
1907 - The plant began producing medicines on an industrial scale. The first drugs produced at the plant included disinfectants, antipyretics and painkillers, one of the most famous - Kalmopirin (acetylsalicylic acid) is still used today.
1914 - 28 drugs from the Gedeon Richter plant were patented.
1920 – about 150 types of drugs are already on the market. The Company successfully applies the experience gained from the development of these drugs, providing an even greater variety of products on the domestic market.
1930 - Gedeon Richter becomes one of the leaders in the production of Estrone in the world. By the end of the year, the Company will open 10 representative offices. At the same time, the Company begins in-depth study and development of synthetic drugs.
Between the two world wars, the Company had 10 subsidiaries, 40 foreign representative offices and a network on five continents. At the end of the Second World War, Gedeon Richter became one of Hungary's largest exporters.
1949 - the creation of the CMEA, the Gedeon Richter plant focuses its production on the market of the CMEA member countries. All export-import transactions within the framework of CMEA are carried out centrally through the state foreign trade enterprise "Medimpex".
1950s - Along with the increase in the volume of export operations, during this period the research direction is developing, work is underway to create steroid hormonal drugs. Several original drugs have been developed and patented.
1960s - technical re-equipment of the enterprise, strengthening of the research base.
1968 - The company establishes a new and improved pharmacological center, in which a number of developments are carried out under the guidance of experts.
1974 – the new drug Cavinton enters the market, one of the Company’s most successful drugs.
After 1992, the Gedeon Richter company was corporatized. Creation of our own market network and a network of representative offices in various countries of the world.
1995 - September 8 - decision of the management of the Gedeon Richter company to create an organized market network in the CIS countries.
XXI century - eastern part of central Europe with a market network on five continents. About 100 countries receive the plant's products. JSC Gedeon Richter has 29 Representative Offices in 31 countries, 38 commercial and wholesale enterprises, 5 manufacturing enterprises, not including Hungarian factories (Russia, Romania, Poland, Germany, India). The unique market network covers the EU countries, the USA, the CIS countries, Japan and the eastern region. JSC Gedeon Richter is a regional multinational enterprise.